RareResearch.AI
← Back to atlas

F884L

Category 3/4 — Most DruggableUncertain significanceLumenal · predictedσ-1 candidateSource card
PhenylalanineLeucine at position 884 · C-terminal ER-lumenal (calcium binding, calmodulin, chaperone) · WFS1 (Wolframin)

Interactive 3D Structure

Wild-type reference
Wild-type F884 — hydrogen bond to D880
Fullscreen ↗
DynaMut2 mutant · F884L
Mutant L884 — polar contact contact to D880 lost
Fullscreen ↗

Bond changes · DynaMut2 interaction analysis

0 lost0 gained4 preserved
Interaction typeWild-type partnerMutant partnerStatus
Hydrogen bondD880D880Preserved
Polar contactD880D880Preserved
Polar contactL887L887Preserved
HydrophobicD880D880Preserved

Lost / gained / preserved interatomic contacts at the variant residue, from the DynaMut2 (Arpeggio) interaction analysis of the wild-type and energy-minimized mutant structures.

Computational Predictions

DynaMut2 ΔΔG
-0.06kcal/mol
Destabilising — mild
AlphaMissense
0.838
likely pathogenic
AlphaFold pLDDT
76
model confidence
Schema
Cat 3/4
Category 3/4 — Most Druggable

Clinical Evidence

ClinVar classificationUncertain significance
Review statuscriteria provided, single submitter
Associated conditions
Population frequency (gnomAD v4)Ultra-rare · AF 0.00020%
cDNA changec.2652C>G
ClinVar accessionVCV002806820
Last evaluated2023/11/13 00:00

Observed at very low frequency in gnomAD.

Full Variant Card

WFS1 Wolframin — F884L Variant Card

Molecular Atlas Pilot · RareResearch.AI · Generated by wolfram-variant-card skill

Phenylalanine → Leucine at position 884. C-terminal ER-lumenal (calcium binding. ClinVar Uncertain significance, AlphaMissense 0.838, DynaMut2 ΔΔG -0.06 kcal/mol (destabilising).


Identity

FieldValue
VariantF884L (p.Phenylalanine884Leucine)
DNA changec.2652C>G
Gene · ProteinWFS1 · Wolframin (890 aa)
UniProtO76024 · WFS1_HUMAN
ClinVar accessionVCV002806820
Amino acid changePhenylalanine (F) → Leucine (L)

Structural Context

FieldValue
AlphaFold modelAF-O76024-F1, v6
pLDDT at residue 88475.56 — well-folded
DomainC-terminal ER-lumenal (calcium binding, calmodulin, chaperone)
Position contextC-terminal lumenal domain · position 884 projects into the ER lumen
IDR flagNo — pLDDT above 50 threshold

UniProt features at this position:

(none catalogued)

Position 884 sits in the C-terminal lumenal domain (residues 653–869), wolframin's largest soluble region. This domain projects into the ER lumen and is implicated in calcium handling, ER stress sensing, and protein–protein interactions with ATF6 and Na+/K+ ATPase β1. The wild-type residue is large aromatic hydrophobic (phenylalanine); the mutant is medium hydrophobic (leucine — branched). The chemistry shift implies altered local packing, hydrogen-bonding, and/or electrostatics at this site.


Computational Predictions

AlphaMissense

FieldValue
am_pathogenicity0.8376
am_classlikely pathogenic
InterpretationLikely pathogenic (threshold 0.564)

DynaMut2

FieldValue
ΔΔG (kcal/mol)-0.06 (Destabilising)
Job ID178092112774
Result URLhttps://biosig.lab.uq.edu.au/dynamut2/results_prediction/178092112774

Clinical Evidence

FieldValue
ClassificationUncertain significance
Review statuscriteria provided, single submitter
Last evaluated2023/11/13 00:00
InheritanceInheritance pattern not specified in ClinVar entry; WFS1 has both AD and AR presentations.
WFS1 variant landscapeF884L is 1 of ~326 pathogenic-spectrum variants in WFS1 (out of 2,243 catalogued in ClinVar)

(no conditions catalogued)


Research Path Decision Tree

ΔΔG < 2  + binding site affected   →  CATEGORY 3 — docking experiments
ΔΔG 2–4                            →  CATEGORY 2 — pharmacological chaperones
ΔΔG > 4                            →  CATEGORY 1 — gene therapy
pLDDT < 50                         →  CATEGORY 5 — IDR, experimental only
Stable fold + functional site hit  →  CATEGORY 4 — site-specific docking

Final Schema Categorization

Category 3/4 — Most Druggable

<strong>Category 3/4 — Most Druggable</strong><br/><br/>|ΔΔG|=0.06 < 2 kcal/mol (fold intact) + AlphaMissense 0.838 confirms functional impact. Specific local contacts disrupted — priority for docking and pharmacological chaperone screening.

Why this card matters. Wolframin's fold survives this substitution (|ΔΔG|=0.06 kcal/mol). The pathogenic signal is real — AlphaMissense places it at 0.838. Protein still folds, but a specific local site is broken. Pharmacological chaperones and small-molecule binders are the rational therapeutic vector.


Files in this folder

  • AF-O76024-F1-model_v6.pdb — AlphaFold structure
  • F884L_molstar_viewer.html — interactive 3D viewer (auto-highlights position 884 with ball-and-stick + neighbors within 5Å)
  • F884L_variant_card.md — this card (source of truth)
  • F884L_variant_card.html — styled printable card
  • F884L_dynamut2_summary.html — clean offline DynaMut2 result card
  • dynamut2_result.json — structured result data
  • dynamut2_result_page.html — local snapshot of the Biosig result page (asset URLs absolutized)
  • F884L_wildtype_interactions.pse / F884L_mutant_interactions.pse — PyMOL sessions

Generated by wolfram-variant-card skill · RareResearch.AI Molecular Atlas Every assumption documented. Every score sourced.

Therapeutic Strategy Handoff · prediction

Feed this card to Wolfram Intelligence

Download the F884L PDF below and upload it to Wolfram Intelligence to generate therapeutic-strategy proposals — guanidinium mimetics, sigma-1 agonist docking, NAC thiol-capping. NAC is already on the bench-testing list.

Download F884L PDF card ↓Strategies are AI-generated predictions, not validated therapeutics.